Tazobactum%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many beta-lactamase enzymes produced by bacteria, thereby extending its spectrum of activity. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections (including diabetic foot infections) * Community-acquired pneumonia * Nosocomial pneumonia * Febrile neutropenia (empiric treatment) * Bacterial meningitis (when indicated by susceptibility) ## Adult Dosing Standard dosing is 3.375 grams every 6 hours or 4.5 grams every 6 or 8 hours, administered intravenously. The choice of dose and frequency depends on the severity and type of infection, as well as local susceptibility patterns. Specific protocols may dictate dosing for certain indications (e.g., febrile neutropenia). ## Pediatric Dosing * **Infants and Children < 2 months:** Dosing is not well established. Consult specialized resources or institutional protocols. * **Children ≥ 2 months:** Dosing is typically based on piperacillin weight, with tazobactam included in a fixed ratio. Common regimens range from 93.75 mg/kg/day to 112.5 mg/kg/day, divided every 6 or 8 hours. For children weighing > 50 kg, adult doses should be used. * Examples: 93.75 mg/kg/dose (75 mg piperacillin/18.75 mg tazobactam per kg) every 8 hours, or 112.5 mg/kg/dose (90 mg piperacillin/22.5 mg tazobactam per kg) every 6 hours. * Maximum dose per administration should generally not exceed the adult dose of 4.5 grams. ## Dose Adjustments * **Renal Impairment:** * CrCl ≥ 40 mL/min: No dose adjustment needed. * CrCl 20-39 mL/min: Administer the usual dose every 8 hours. * CrCl < 20 mL/min: Administer the usual dose every 12 hours. * For patients on intermittent hemodialysis, administer the usual dose every 8 hours and administer an additional dose equal to one-half of the usual dose after each dialysis session. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation. * History of a severe allergic reaction (e.g., anaphylaxis) to a beta-lactam antibiotic. ## Adverse Effects Common adverse effects include diarrhea, nausea, vomiting, rash, headache, insomnia, constipation, and leukopenia. Serious adverse effects may include *Clostridioides difficile*-associated diarrhea, seizures (especially with high doses or renal impairment), hypersensitivity reactions (including anaphylaxis), and hematologic abnormalities. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the action of neuromuscular blocking agents. * **Warfarin:** Piperacillin may decrease the efficacy of warfarin. Monitor INR closely. * **Methotrexate:** Piperacillin may decrease methotrexate clearance. Monitor methotrexate levels. ## Monitoring * Renal function (CrCl) for dose adjustment. * Liver function tests (LFTs). * Complete blood count (CBC) with differential, especially with prolonged therapy or in patients with neutropenia. * Signs and symptoms of infection. * Signs and symptoms of *Clostridioides difficile*-associated diarrhea. * Signs and symptoms of hypersensitivity reactions. ## Clinical Pearls * Piperacillin/tazobactam is a potent antibiotic but is susceptible to certain extended-spectrum beta-lactamases (ESBLs) and carbapenemases. Susceptibility testing is crucial. * The 4.5 g formulation contains 4 g piperacillin and 0.5 g tazobactam. The 3.375 g formulation contains 3 g piperacillin and 0.375 g tazobactam. * Reconstituted solutions should be used within 24 hours at room temperature or within 48 hours if refrigerated. * Infusion-related adverse events (e.g., phlebitis) can be minimized by slow intravenous infusion over at least 30 minutes. *** *This information is intended for healthcare professionals and does not substitute for professional medical advice. Always consult the most current prescribing information, institutional protocols, and clinical guidelines before making any treatment decisions.*